Lipid-Based Nanoparticulate Drug Delivery Systems: Preparation, Biomedical Applications, and Evaluation

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".

Deadline for manuscript submissions: 31 December 2024 | Viewed by 717

Special Issue Editors


E-Mail Website
Guest Editor
Department of Pharmaceutical Technology and Biopharmaceutics, Faculty of Pharmacy, Medical University of Sofia, 1000 Sofia, Bulgaria
Interests: pharmaceutical nanothechnology; nanosized drug delivery carriers; nanovesicles; targeted drug and gene delivery; pharmacokinetics

E-Mail Website
Guest Editor
Department of Pharmaceutical Technologies, Faculty of Pharmacy, Medical University of Varna, 9000 Varna, Bulgaria
Interests: emulsion polymerization; drug stability; pharmaceutical nanotechnology; pharmaceutical research and development; pharmacokinetics
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Pharmaceutical Technologies, Faculty of Pharmacy, Medical University of Varna, 9000 Varna, Bulgaria
Interests: vesicular systems; niosomes; stimuli-sensitive nanocarriers; inorganic nanoparticles
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Pharmaceutical Technologies, Faculty of Pharmacy, Medical University of Varna, 9000 Varna, Bulgaria
Interests: drug stability; silver nanoparticles; polymeric nanoparticles; pharmaceutical analysis; transdermal and mucosal drug permeation
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Lipid-based nanoparticulate drug delivery systems (i.e., liposomes, nanostructured lipid carriers, solid lipid nanoparticles, niosomes, etc.) have captured significant attention at both preclinical and clinical levels due to their advantageous characteristics, including biocompatibility, safety, scaling up feasibility, as well as their promising biopharmaceutical performance and therapeutic outcomes. Lipid-based nanosystems are suitable carriers for various types of cargo—drugs, phytoconstituents, nucleic acids, and monoclonal antibodies—and are capable of improving their unfavorable physicochemical/pharmacokinetic characteristics and stability issues. These nanoscale systems exhibit the potential to enhance drug bioavailability, to provide a controlled release profile, and to achieve targeted delivery via suitable surface tailoring by tuning their physicochemical characteristics at the (pre)formulation stage.

This Special Issue aims to summarize recent advances in lipid-based nanoparticulate drug delivery systems to highlight some of the future directions in this research area. Submissions of original research and review articles demonstrating progress in the field are welcome.

Prof. Dr. Denitsa Momekova
Dr. Velichka Andonova
Dr. Viliana Eduardova Gugleva
Dr. Nadezhda Ivanova
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at mdpi.longhoe.net by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • liposomes
  • nanoemulsions
  • nanostructured lipid carriers
  • niosomes
  • solid lipid nanoparticles
  • targeted drug delivery

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

17 pages, 1389 KiB  
Article
Solid Lipid Nanoparticles Loaded with Dexamethasone Palmitate for Pulmonary Inflammation Treatment by Nebulization Approach
by Hsin-Hung Chen, Chen-Hsiang Sang, Chang-Wei Chou, Yi-Ting Lin, Yi-Shou Chang and Hsin-Cheng Chiu
Pharmaceutics 2024, 16(7), 878; https://doi.org/10.3390/pharmaceutics16070878 - 29 Jun 2024
Viewed by 345
Abstract
Pneumonia stands as the leading infectious cause of childhood mortality annually, underscoring its significant impact on pediatric health. Although dexamethasone (DXMS) is effective for treating pulmonary inflammation, its therapeutic potential is compromised by systemic side effects and suboptimal carrier systems. To address this [...] Read more.
Pneumonia stands as the leading infectious cause of childhood mortality annually, underscoring its significant impact on pediatric health. Although dexamethasone (DXMS) is effective for treating pulmonary inflammation, its therapeutic potential is compromised by systemic side effects and suboptimal carrier systems. To address this issue, the current study introduces solid lipid nanoparticles encapsulating hydrophobic dexamethasone palmitate (DXMS-Pal-SLNs) as an anti-inflammatory nanoplatform to treat pneumonia. The specialized nanoparticle formulation is characterized by high drug loading efficiency, low drug leakage and excellent colloidal stability in particular during nebulization and is proficiently designed to target alveolar macrophages in deep lung regions via local delivery with the nebulization administration. In vitro analyses revealed substantial reductions in the secretions of tumor necrosis factor-α and interleukin-6 from alveolar macrophages, highlighting the potential efficacy of DXMS-Pal-SLNs in alleviating pneumonia-related inflammation. Similarly, in vivo experiments showed a significant reduction in the levels of these cytokines in the lungs of mice experiencing lipopolysaccharide-induced pulmonary inflammation after the administration of DXMS-Pal-SLNs via nebulization. Furthermore, the study demonstrated that DXMS-Pal-SLNs effectively control acute infections without causing pulmonary infiltration or excessive recruitment of immunocytes in lung tissues. These findings highlight the potential of nebulized DXMS-Pal-SLNs as a promising therapeutic strategy for mitigating pneumonia-related inflammations. Full article
Back to TopTop